SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the pricing of an upsized secondary public offering of 23.7 million shares of its common stock by certain of its stockholders (the “Selling Stockholders”) at a price to the public of $29.50 per share. In addition, the Selling Stockholders have granted the underwriters a 30-day over-allotment option to purchase up to an additional 3.555 million shares of common stock. The offering is expected to close on March 9, 2015, subject to customary closing conditions. Catalent is not selling any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders.
Help employers find you! Check out all the jobs and post your resume.
